152 related articles for article (PubMed ID: 913055)
21. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease.
Martins da Costa C; Baldwin D; Portmann B; Lolin Y; Mowat AP; Mieli-Vergani G
Hepatology; 1992 Apr; 15(4):609-15. PubMed ID: 1551638
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of administered triethylene tetramine dihydrochloride in humans.
Kodama H; Murata Y; Iitsuka T; Abe T
Life Sci; 1997; 61(9):899-907. PubMed ID: 9284083
[TBL] [Abstract][Full Text] [Related]
23. The effect of copper chelating drugs on liver iron mobilization in the adult rat.
Cohen NL; Keen CL; Lönnerdal B; Hurley LS
Biochem Biophys Res Commun; 1983 May; 113(1):127-34. PubMed ID: 6860330
[TBL] [Abstract][Full Text] [Related]
24. Effects of some chelating agents on urinary copper excretion by the rat.
Jones MM; Singh PK; Zimmerman LJ; Gomez M; Albina ML; Domingo JL
Chem Res Toxicol; 1995; 8(7):942-8. PubMed ID: 8555409
[TBL] [Abstract][Full Text] [Related]
25. A mechanism for the action of penicillamine in the treatment of Wilson's disease.
Peisach J; Blumberg WE
Mol Pharmacol; 1969 Mar; 5(2):200-9. PubMed ID: 4306792
[No Abstract] [Full Text] [Related]
26. Copper chelating agents. A comparison of cupruretic responses to various tetramines and D-penicillamine.
Borthwick TR; Benson GD; Schugar HJ
J Lab Clin Med; 1980 Apr; 95(4):575-80. PubMed ID: 7359013
[TBL] [Abstract][Full Text] [Related]
27. Effect of D,L-penicillamine on the urinary excretion of copper and calcium in hepatolenticular degeneration (Wilson's disease).
LITIN RB; GOLDSTEIN NP; RANDALL RV; POWER MH; DIESSNER GR
Neurology; 1960 Feb; 10():123-6. PubMed ID: 14417516
[No Abstract] [Full Text] [Related]
28. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
29. Wilson's disease: assessment of D-penicillamine treatment.
Van Caillie-Bertrand M; Degenhart HJ; Luijendijk I; Bouquet J; Sinaasappel M
Arch Dis Child; 1985 Jul; 60(7):652-5. PubMed ID: 4026361
[TBL] [Abstract][Full Text] [Related]
30. Wilson's disease: current status.
Yarze JC; Martin P; Muñoz SJ; Friedman LS
Am J Med; 1992 Jun; 92(6):643-54. PubMed ID: 1605146
[TBL] [Abstract][Full Text] [Related]
31. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent.
Walshe JM
Lancet; 1969 Dec; 2(7635):1401-2. PubMed ID: 4188283
[No Abstract] [Full Text] [Related]
32. The effect of long term treatment with penicillamine on the copper content in the liver in patients with Wilson's disease.
Marecek Z; Heyrovský A; Volek V
Acta Hepatogastroenterol (Stuttg); 1975 Oct; 22(5):292-6. PubMed ID: 1199668
[TBL] [Abstract][Full Text] [Related]
33. 1H NMR-based metabolomics investigation of copper-laden rat: a model of Wilson's disease.
Xu J; Jiang H; Li J; Cheng KK; Dong J; Chen Z
PLoS One; 2015; 10(4):e0119654. PubMed ID: 25849323
[TBL] [Abstract][Full Text] [Related]
34. Progressive atrophy of pancreatic acinar tissue in rats fed a copper-deficient diet supplemented with D-penicillamine or triethylene tetramine: morphological and physiological studies.
Smith PA; Sunter JP; Case RM
Digestion; 1982; 23(1):16-30. PubMed ID: 7084566
[TBL] [Abstract][Full Text] [Related]
35. The mechanism of excretion of trientine from the rat kidney: trientine is not recognized by the H+/organic cation transporter.
Kobayashi M; Tanabe R; Sugawara M; Iseki K; Miyazaki K
J Pharm Pharmacol; 1997 Apr; 49(4):426-9. PubMed ID: 9232542
[TBL] [Abstract][Full Text] [Related]
36. Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
Kirk FT; Munk DE; Swenson ES; Quicquaro AM; Vendelbo MH; Schilsky ML; Ott P; Sandahl TD
Hepatology; 2024 May; 79(5):1065-1074. PubMed ID: 38088886
[TBL] [Abstract][Full Text] [Related]
37. [Checking of urinary copper in patients with Wilson's disease during treatment with D-penicillamine].
Indaco A; Pellegrino L; Campanella G
Acta Neurol Quad (Napoli); 1979; 39():160-4. PubMed ID: 555232
[No Abstract] [Full Text] [Related]
38. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
39. Combination treatment with penicillamine and trientine in a patient with Wilson's disease.
Kobayashi S; Kodama H; Inuzuka R; Mori Y; Yanagawa Y
Pediatr Int; 2005 Oct; 47(5):589-91. PubMed ID: 16190972
[No Abstract] [Full Text] [Related]
40. Antiangiogenic therapy through copper chelation.
Sproull M; Brechbiel M; Camphausen K
Expert Opin Ther Targets; 2003 Jun; 7(3):405-9. PubMed ID: 12783576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
